 BOSTON, Sept. 20, 2021 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq: RYTM, a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has completed its supplemental New Drug Application sNDA to the U.S. Food and Drug Administration FDA for IMCIVREE setmelanotide for the treatment of obesity and control of hunger in adult and pediatric patients 6 years of age and older with Bardet-Biedl syndrome BBS or Alström syndrome. 